Cart (0 Items)
Your cart is currently empty.
View ProductsSize | 100ug |
---|---|
Brand | Arovia |
Product type | Recombinant Proteins |
Product name | Recombinant Human SUMF1, N-His |
---|---|
Origin species | Human |
Expression system | Prokaryotic expression |
Molecular weight | 30.00 kDa |
Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
Form | Liquid |
Delivery condition | Dry Ice |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
Brand | Arovia |
Host species | Escherichia coli (E.coli) |
Fragment Type | Glu113-Ser356 |
Aliases /Synonyms | Formylglycine-generating enzyme, FGE, SUMF1, Sulfatase-modifying factor 1, C-alpha-formylglycine-generating enzyme 1 |
Reference | ARO-P13242 |
Note | For research use only. |
Recombinant Human SUMF1 is a highly specialized protein that plays a crucial role in various biological processes. This protein is produced through recombinant DNA technology, making it a valuable tool for researchers in the field of biotechnology and medicine. In this article, we will discuss the structure, activity, and applications of Recombinant Human SUMF1.
Recombinant Human SUMF1 is a 352 amino acid protein with a molecular weight of approximately 40 kDa. It is composed of a signal peptide, a propeptide, and a mature peptide. The mature peptide contains the active site of the protein and is responsible for its biological activity.
The crystal structure of Recombinant Human SUMF1 has been determined through X-ray crystallography, revealing a compact globular structure with a central beta-sheet surrounded by alpha-helices. The active site of the protein is located in a deep cleft between two alpha-helices, making it easily accessible for substrate binding.
The primary function of Recombinant Human SUMF1 is the post-translational modification of various sulfatases, which are enzymes involved in the breakdown of complex sugars. This modification, known as sulfation, is essential for the proper functioning of sulfatases.
Recombinant Human SUMF1 catalyzes the transfer of a sulfate group from the donor molecule 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to the target sulfatase, resulting in the formation of an active enzyme. This process is crucial for the degradation of sulfated compounds, such as glycosaminoglycans, which are essential components of connective tissues, cartilage, and bone.
In addition to its role in sulfatase activation, Recombinant Human SUMF1 has also been found to have neuroprotective properties. It has been shown to protect neurons from oxidative stress and promote cell survival in various neurodegenerative diseases, such as Parkinson’s and Alzheimer’s.
Recombinant Human SUMF1 has a wide range of applications in both research and medicine. Its ability to activate sulfatases makes it a valuable tool for studying various biological processes involving sulfated compounds. It is commonly used in studies related to connective tissue disorders, lysosomal storage diseases, and neurodegenerative diseases.
In the field of medicine, Recombinant Human SUMF1 has shown promising results in the treatment of lysosomal storage diseases, such as mucopolysaccharidoses (MPS). These diseases are caused by the deficiency of specific sulfatases, and the administration of Recombinant Human SUMF1 has been shown to improve the activity of these enzymes and alleviate symptoms in patients.
Furthermore, the neuroprotective properties of Recombinant Human SUMF1 make it a potential therapeutic agent for neurodegenerative diseases. Clinical trials are currently underway to evaluate its effectiveness in the treatment of Parkinson’s and Alzheimer’s diseases.
In summary, Recombinant Human SUMF1 is a crucial protein with diverse functions in various biological processes. Its structure and activity have been extensively studied, and its applications in research and medicine are continuously expanding. With its potential therapeutic benefits, Recombinant Human SUMF1 holds great promise for the treatment of various diseases and offers exciting opportunities for further research and development.
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.